As reported by navilyst medical's distributor in (b)(4), in the distributor's warehouse, a small hole was found in the mylar portion of the contrast injection line pouch, breaching the sterility.The device had not provided to a hospital and was returned to navilyst medial for evaluation.
|
A review of the device history records was performed for the reported packaging lot for any deviations related to the reported defect of the complaint.The review confirms that the lot met all material, assembly and performance specifications.The angiodynamics (b)(6) 2015 complaint report was reviewed for the product family of contrast injection lines and the failure mode, "hole in pouch." no adverse trends were identified.The returned sample was visually inspected and the hole in the pouch was confirmed.The hole was in the mylar side of the pouch and is located near the rotating adaptor of the contrast injection line.The "flap" of the hole was pointing outward, but it is difficult to determine if something from the inside of the pouch pushed outward to create the hole, or if something from the outside dug into the pouch.The pouch size is appropriate for the device and the number of pouches per inner box is also appropriate.Although the returned sample did not have a nipro label applied to the pouch,as part of the receiving process at nipro all pouches are removed from their inner boxes and a nipro label (in (b)(6)) is applied to each pouch and inner box.Additional handling may occur if product is 100% visually inspected.The pouches are then re-boxed into the inner boxes by the nipro warehouse employees.The cause of the hole in the pouch is unable to be determined.Potential factors contributing to the damage include: handling of the pouches as they are placed in the inner boxes, handling during transit to nipro warehouse, handling at nipro during the labeling/inspection and re-boxing process.All pouches are 100% inspected per angiodynamics procedures during the sealing and final box processes.The directions for use (dfu) included with the kits contain the following warning: "contents supplied sterile using an ethylene oxide (e) process.Do not use if sterile barrier is damaged." all packaging employees have been made aware of this complaint in order to improve their awareness of the defect and to improve the probability of identifying the defect in the future.
|